Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity in a deal ...

Septerna (SEPN) stock surges as Novo Nordisk (NVO) inks $2.2B deal to develop and commercialize oral obesity drugs. Read more ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise ...

May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business ...